10.01.11
Nutraceutical: Probiotics (BB-12 and L. casei 431)
Indication: Immune function
Source: Br J Nutr, September 7, 2011 [Epub ahead of print].
Research: In this randomized, double-blind, placebo-controlled, parallel-group study, 211 healthy adults were divided into two probiotic groups (receiving BB-12 and L. casei 431, respectively) and two placebo groups. Subjects consumed a minimum of 109 colony-forming units of BB-12 (capsule) or L. casei 431 (dairy drink) or a matching placebo once daily for 6 weeks. After 2 weeks, a seasonal influenza vaccination was given. Plasma and saliva samples were collected at baseline and after 6 weeks for the analysis of antibodies, cytokines and innate immune parameters.
Results: The number of persons experiencing a substantial increase in flu antibodies was significantly greater in both probiotic groups than in the placebo groups. For example, in the BB-12 group 66% had a substantial increase in the specific antibody IgG3 compared to only 4% in the placebo group. Likewise, in the L. casei 431 group 46% had a substantial increase compared to just 2% in the placebo group. Changes from baseline in vaccine-specific plasma IgG, IgG1 and IgG3 were significantly greater in both probiotic groups vs. the corresponding placebo group. The outcomes of this study, as well as data from previous studies on BB-12 and L. casei 431, show that supplementation with these probiotic strains results in a strengthening of various parts of the immune system.
Indication: Immune function
Source: Br J Nutr, September 7, 2011 [Epub ahead of print].
Research: In this randomized, double-blind, placebo-controlled, parallel-group study, 211 healthy adults were divided into two probiotic groups (receiving BB-12 and L. casei 431, respectively) and two placebo groups. Subjects consumed a minimum of 109 colony-forming units of BB-12 (capsule) or L. casei 431 (dairy drink) or a matching placebo once daily for 6 weeks. After 2 weeks, a seasonal influenza vaccination was given. Plasma and saliva samples were collected at baseline and after 6 weeks for the analysis of antibodies, cytokines and innate immune parameters.
Results: The number of persons experiencing a substantial increase in flu antibodies was significantly greater in both probiotic groups than in the placebo groups. For example, in the BB-12 group 66% had a substantial increase in the specific antibody IgG3 compared to only 4% in the placebo group. Likewise, in the L. casei 431 group 46% had a substantial increase compared to just 2% in the placebo group. Changes from baseline in vaccine-specific plasma IgG, IgG1 and IgG3 were significantly greater in both probiotic groups vs. the corresponding placebo group. The outcomes of this study, as well as data from previous studies on BB-12 and L. casei 431, show that supplementation with these probiotic strains results in a strengthening of various parts of the immune system.